Study: US C difficile prevalence fell during COVID-19 pandemicThe prevalence of Clostridioides difficile infection (CDI) in the United States declined during the COVID-19 pandemic, but inpatient mortality and treatment costs were higher, according to a paper published yesterday in Open Forum Infectious Diseases.Using data from the Premier Healthcare Database, researchers with the University of Texas and Texas A&M compared CDI prevalence and inpatient outcomes in the pre-COVID (April 2019 to March 2020) and COVID (April 2020 to March 2021) periods.
Overall, a total of 25,991 inpatients and outpatients with a laboratory-confirmed CDI diagnosis were included in the analysis.
The investigators analyzed data on 22,130 unique patients, who were predominantly older (median age, 68 years), female (57.5%), and White (79.5%).CDI prevalence significantly decreased from the pre-COVID to the COVID period (12.2 CDI cases per 10,000 encounters vs 8.9 per 10,000), driven primarily by a reduction in inpatient CDI prevalence (57.8 per 10,000 vs 49.4 per 10,000), though outpatient CDI prevalence fell as well (2.2 per 10,000 vs 1.5 per 10,000).
But an interrupted time series analysis found no significant difference in the rate ratio (RR) from the pre-COVID to the COVID period for all encounters (RR, 1.04; 95% CI, 0.90 to 1.20) or inpatient encounters (RR, 1.08; 95% CI, 0.98 to 1.19).Patient costs increased by an average of approximately $2,000 from the pre-COVID to the COVID period.